Neurologie mit Schwerpunkt neurovaskuläre Erkrankungen und Neuroonkologie

Neuro-Onkologie

2012

Höring, E., Harter, P.N., Seznec, J., Schittenhelm, J., Bühring, H.J., Bhattacharyya, S., Hattingen, E., Zachskorn, C., Mittelbronn, M., Naumann, U. The “go or grow” potential of gliomas is linked to the neuropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress. Acta Neuropathologica, Epub ahead

2011

Seznec, J., Silkenstedt, B., Naumann, U. Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma
J Neurooncol. (2011) 101(3):365-377

Gaub, P., Yoshi, Y., Wuttke, A,. Naumann, U., Schnichels, S., Heiduschka, P., Di Giovanni, S. The histone acetyltransferase p300 promotes intrinsic axonal regeneration.
Brain (2011)  134:2134-2148

Seznec, J., Naumann, U. Microarray Analysis in a Cell Death Resistant Glioma Cell Line to Identify Signaling Pathways and Novel Genes Controlling Resistance and Malignancy.
Cancers 2011 3:2827-2843

2010

Seznec, J., Weit, S., Naumann, U. Gene expression profile in a glioma cell line resistant to cell death induced by the chimeric tumorsuppressor-1 (CTS-1), a dominant positive p53 – the role of NFkB
Carcinogenesis (2010) 3:411-418

2009

Tedeschi, A., Nguyen, T., Steele, S.U., Feil, S., Feil, R., Naumann, U. , Di Giovanni, S. The tumour suppressor p53 regulates cGKI expression during neuronal maturation and is required for cGMP-dependent growth cone collapse.
J. Neuro Sci. (in press)

Naumann, U., Weller, M. Modulating TGF-ß receptor signaling: a novel approach of cancer therapy. In Transforming Growth Factor-beta in Cancer Therapy, published in Beverly Teicher's Methods in Molecular Biology series on "Cancer Drug Discovery and Development" (Humana Press, USA 2009)

2008 

Weinmann, L., Wischhusen, J., Demma, M.J., Naumann, U., Roth, P., DasMahapatra, B., Weller, M. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Cell Death Differ. (2008) 15:718-729

Naumann, U., Maass, P., Gleske, A.K., Aulwurm, S., Weller, M., Eisele, G. Glioma gene therapy with soluble transforming growth factor-ß receptors II and III.
Int J. Oncol. (2008) 33:759-765

2007

Naumann, U., Bähr, O., Wolburg, H., Altenberend, S., Wick, W., Liston, P., Ashkenazi, A., and Weller, M. Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice.
Gene Ther. (2007) 14:147-161; 14:1434-1437

2006

Weiler, M., Bähr, O., Hohlweg,U., Naumann, U., Rieger, J., Huang, H., Tabatabai, G., Ohgaki, H., Weller,M., Wick, W. BCL-xL, apoptosis and motility: move to survive or survive to move?
Cell Death Differ. (2006) 13:1156-1169

Busche, A., Goldmann, T., Naumann, U., Steinle, A. Brandau, S. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene
A. Hum. Gene Ther. 17 (2006): 135-146

Naumann, U., Huang, H., Wolburg, H., Wischhusen, J., Weit, S., Ohgaki, H., Weller, M. PCTAIRE3 and PIG3: potential mediators of glioma cell death by CTS-1, a dominant-positive p53-derived tumor suppressor.
Cancer Gene Ther. (2006) 13:469-478

Wick, W., Naumann, U., und Weller, M. (2006). Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma.
Current pharmaceutical design 12, 341-349

Hirrlinger PG, Scheller A, Braun C, Hirrlinger J, Kirchhoff F. Temporal control of gene recombination in astrocytes by transgenic expression of the tamoxifen-inducible DNA recombinase variant CreERT2.
Glia. 2006 Jul;54(1):11-20

2005

Amatya, V.J., Naumann, U., Weller, M., Ohgaki, O.TP53 promoter methylation in human gliomas; Acta Neuropathologica 110 (2005): 178-184

Hirrlinger PG, Scheller A, Braun C, Quintela-Schneider M, Fuss B, Hirrlinger J, Kirchhoff F.Expression of reef coral fluorescent proteins in the central nervous system of transgenic mice.
Mol. Cell Neurosci. 2005 Nov;30(3):291-303

2004

Naumann, U., Wick, W., Beschorner, R., Meyermann, R., Weller, M. Expression and functional activity of osteoprotegerin in human malignant glioma.
Acta Neuropathol. 107 (2004):17-22

Naumann, U., Wick, W., Beschorner, R., Meyermann, R., Weller, M. Reply to Lorenz et al.: Osteoprotegerin in the central nervous system.
Acta Neuropathol. 107 (2004): 578

Herrlinger, U., Aulwurm, S., Strik, H., Weit, S., Naumann, U., Weller, M. MIP-1alpha antagonizes the effect of a GM-CSF-enhanced subcutaneous vaccine in a mouse glioma model.
J. Neurooncol. 66 (2004): 147-154

Naumann, U., Wischhusen, J., Weit, S., Rieger, J., Wolburg, H., Massing. U., Weller, M. Alkyphosphocholine-induced glioma cell death is BCL-XL-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation.
Cell Death and Differ. 11 (2004): 1326-1341

Biglari, A., Bataille, D., Naumann, U., Weller, M., Castro, M.G., Lowenstein, P.R. Effects of ectopic decorin in modulating intracranial glioma progress in vivo, a rat syngeneic model.
Cancer Gene Ther. 11 (2004):721-732 

2003 

Naumann, U., Waltereit, R., Schulz, J.B., Weller, M. Adenoviral (full length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma.
J. Neuro-Oncology 61 (2003): 7-15

Naumann, U., Schmidt, F., Wick, W., Frank, B., Weit, S., Gilllissen, B., Daniel, P., Weller, M. Adenoviral natural born gene therapy for malignant glioma.
Human Gene Ther. 14 (2003): 1235-1246

Platten, M., Kretz, A., Naumann, U., Aulwurm, S., Egashira, K., Isenmann, S., Weller M. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas.
Ann. Neurol. 54 (2003): 388-392

Wischhusen, J., Naumann, U., Ohgaki, H., Rastinejad, F., Weller, M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent cell death.
Oncogene 22 (2003): 8233-8145

Friese, M.A., Platten, M., Lutz, S.Z., Naumann, U., Aulwurm, S., Bischof, F., Bühring, H.J., Dichgans, J., Rammensee, H.G., Steinle, A., Weller, M. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Cancer Res. 63 (2003) : 8996-9006.

2001

Roth, W., Wagenknecht, B., Klumpp, A., Naumann, U., Hahne, M., Tschopp, J., Weller, M. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis.
Cell Death and Diff. 8 (2001): 403-410

Streffer, J.R., Rimner, A., Rieger, J., Naumann, U., Rodemann, H.P., and Weller, M. Bcl-2 family protein expression modulates radiosensitivity in human glioma cells.
J. Neuro-Oncol. 56 (2001) : 43-49

Schmidt, F., Rieger, J., Wischhusen, J., Naumann, U., Weller, M. Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage.
Eur. J. Pharmacol. 412 (2001): 21-25

Weber, R.G., Rieger, J., Naumann, U., Lichter, P., Weller, M. Chromosomal imbalances associated with the response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines.
Int. J. Cancer 91 (2001): 213-218

Rimner, A., Wischhusen, J., Naumann, U., Gleichmann, M., Steinbach, J.P., Weller, M. Identification by suppression subtractive hybridization of p21 as a radio-inducible gene in human glioma cells.
Anticancer Res. 21 (2001): 3505-3508

Leitlein, J., Aulwurm, S., Waltereit, R., Naumann, U., Wagenknecht, B., Garten, W., Weller, M., Platten. M. Processing of immunosuppressive pro-TGF-beta 1, 2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases.
J.Immunol. 166 (2001): 7238-7243

Röhn, T.A., Wagenknecht, B., Roth, W., Naumann, U., Gulbins, E., Krammer, P.H., Walczak, H., Weller, M. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Oncogene 20 (2001): 4128-4137

Naumann, U., Kügler, S., Wolburg, H., Wick, W., Rascher, G., Schulz, J.B., Conseiller, E., Bähr, M., Weller, M. Chimeric tumor suppressor 1 (CTS1), a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.
Cancer Res. 61 (2001): 5833-5842

Naumann, U., Weit, S., Wischhusen, J., Weller, M. Diva/Boo is a negative regulator of cell death in human glioma cells.
FEBS Let. 505 (2001): 23-26

2000

Vietor, M., Winter, S., Groscurth, P., Naumann, U., Weller, M. On the significance of telomerase activity in human malignant glioma cells.
Eur. J. Pharmacol. 407 (2000): 27-37

1999

Roller, A., Bähr, O.R., Streffer, J., Winter, S., Heneka, M., Deininger, M., Meyermann, R., Naumann, U., Gulbins, E., Weller, M. Selective potentation of drug cytotoxicity by NSAID in human glioma cells: The role of COX-1 and MRP.
Biochem. Biophys. Res. Comm. 259 (1999): 600-605

Pohl, U., Wagenknecht, B., Naumann, U., Weller, M. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Cell. Physiol. Biochem. 9 (1999): 29-37

Roth, W., Isenmann, S., Naumann, U., Kügler, S., Bähr, M., Dichgans, J., Ashkenazi, A., Weller, M. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in absence of neurotoxicity.
Biochem. Biophys. Res. Comm. 265 (1999): 479-483

Wagenknecht, B., Glaser, T., Naumann, U., Kügler, S., Isenmann, S., Bähr, M., Korneluk, M., Liston, P., Weller, M. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma.
Cell Death and Diff. 6 (1999): 370-376

Wick, W., Furnari, F.B., Naumann, U., Cavanee, W.K., Weller, M. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.
Oncogene 18 (1999): 3936-3943

Bartussek, C., Naumann, U., Weller, M. Accumulation of p53 modulates the growth, clonogenicity and radiochemosensitivity of malignant glioma cells independently of their endogenous p53 status.
Exp. Cell. Res. 253 (1999): 432-439

Münz, C., Naumann, U., Grimmel, C., Rammensee, H.G., Weller, M. TGF-beta-independent induction of immunogenicity by decorin gene tansfer in human malignant glioma cells.
Eur. J. Immunol. 29 (1999): 1032-1040

Naumann, U., Weit, S., Rieger, L., Meyermann, R., Weller, M. p27 modulates cell cycle progression and chemosensitivity in human malignant glioma.
Biochem. Biophys. Res. Comm. 261 (1999): 890-896

Ständer, M., Naumann, U., Wick, W., Weller, M. Transforming growth factor-beta and p21: multiple molecular targets of decorin-mediated suppression of neoplastic growth.
Cell Tissue Res. 296 (1999): 221-227

1998

Rieger, J., Naumann, U., Glaser, T., Ashkenazi, A., Weller, M. Apo2 ligand: a novel lethal weapon against malignant glioma?
FEBS letters 427 (1998): 124-148

Ständer, M., Naumann, U., Dumitrescu, L., Heneka, M., Löschmann, P., Gulbins, E., Dichgans, J., Weller, M. Decorin gene transfer-mediated suppression of TGF-ß synthesis abrogates experimental malignant glioma growth in vivo.
Gene Therapy 5 (1998): 1187-1194

Naumann, U., Weller, M. Retroviral Bax gene tranfer fails to sensitize malignant glioma cells to CD95L-induced apoptosis and cancer chemotheraapy.
Int. J. Cancer 77 (1998): 1-4

Naumann, U., Durka, S., Weller, M. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?
Oncogene 17 (1998): 1567-75

1996

Naumann, U., Eisenmann-Tappe, I, Rapp, U.R: Role of Raf kinases in development and growth of tumors
Rec. Res. Canc. Res. 143 (1996): 237-244

Neuro-Immunologie

Bischof F, Wienhold W, Wirblich C, Malcherek G, Zevering O, Kruisbeek AM, Melms A. Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes.
ProcNatlAcadSci U S A, 2001 Oct 9;98(21):12168-73.

Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, Bühring HJ, Dichgans J, Rammensee HG, Steinle A, Weller M. NKG2D-mediated immunogene therapy of experimental gliomas.
Cancer Res. 2003 Dec 15;63(24):8996-9006.

Bischof F, Hofmann M, Schumacher TNM, Vyth-Dreese FA, Weissert R, Schild H, Kruisbeek AM, Melms A. Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers.
J Immunol, 2004 Mar 1;172(5) 2878-2884.

Bischof F, Bins A, Dürr M, Zevering Y, Melms A, Kruisbeek AM. A structurally available encephalitogenic epitope of myelin oligodendrocyte glycoprotein specifically induces a diversified pathogenic autoimmune response.
J Immunol, 2004 Jul 1;173(1):600-6.

Bischof F, Nägele T, Wanders RJA, Trefz FK, Melms A. 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency in an Adult withLeukoencephalopathy.
Ann Neurol. 2004;56(5):727-730.

Magnus T, Schreiner B, Korn T, Jack C, Guo H, Antel J, Ifergan I, Chen L, Bischof F, Bar-Or A, Wiendl H. Microglial expression of the B7-family member B7H1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS.
J. Neurosci. 2005 25: 2537-2546.

Amend B, Doster H, Lange C, Dubois E, Kalbacher H, Melms A, Bischof F. Induction of autoimmunity by expansion of autoreactive CD4+CD62Llo cells in vivo.
J Immunol. 2006 Oct 1;177(7):4384-90.

Lange C, Dürr M, Doster H, Melms A, Bischof F. Dendritic cell-regulatory T-cell interactions control self-directed immunity.
Immunol Cell Biol. 2007 Nov-Dec;85(8):575-81.

Lange C, Doster H, Steinbach K, Kalbacher H, Scholl M, Melms A, Bischof F. Differential modulation of CNS-specific effector and regulatory T cells during tolerance induction by recombinant invariant chains in vivo. Brain Behav Immun. 2009 Aug;23(6):861-7.

Lange C, Scholl M, Melms A, Bischof F. CD62L(high) Treg cells with superior immunosuppressive properties accumulate within the CNS during remissions of EAE.
Brain Behav Immun. 2011 Jan;25(1):120-6.

Bischof F. Acute inflammatory neuropathies: New evidence for disease classification from Japan. J NeurolNeurosurg Psychiatry. 2011;82:239.

Klose J, Schmidt NO, Melms A, Dohi M, Miyazaki J, Bischof F, Greve B. Suppression of experimental autoimmune encephalomyelitis by interleukin-10 transduced neural stem/progenitor cells. J Neuroinflammation. 2013,10:117.

Bender B, Heine C, Danz S, Bischof F, Reimann K, Bender M, Nägele T, Ernemann U, Korn A. Diffusion restriction of the optic nerve in patients with acute visual deficit. J Magn Reson Imaging. 2013.

Seeger A, Kramer U, Bischof F, Schuettauf F, Ebner F, Danz S, Ernemann U, Hauser TK. Feasibility of Noninvasive Diagnosis and Treatment Planning in a Case Series with Carotid-Cavernous Fistula using High-Resolution Time-Resolved MR-Angiography with Stochastic Trajectories (TWIST) and Extended Parallel Acquisition Technique (ePAT 6) at 3 T. Clin Neuroradiol. 2014 Mar 6.

Maricic I, Halder R, Bischof F, Kumar V. Dendritic Cells and Anergic Type I NKT Cells Play a Crucial Role in Sulfatide-Mediated Immune Regulation in Experimental Autoimmune Encephalomyelitis. J. Immunol 2014.

Seeger A, Klose U, Bischof F, Strobel J, Ernemann U, Hauser TK. Zoomed EPI DWI of Acute Spinal Ischemia Using a Parallel Transmission System. Clin Neuroradiol. 2014 Aug 29

Silber T, Ziemann U, Ernemann U, Bischof F. Analysis of periinterventional complications of intracranial angioplasty and stenting: A single center experience. E. J Radiol. 2014.